Dopamine agonists and valvular heart disease.
Kast
Richard E
RE
Altschuler
Eric L
EL
D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects*; D004873:Ergolines / Q000009:adverse effects; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D008784:Methysergide / Q000009:adverse effects*; D010479:Pergolide / Q000009:adverse effects; D044403:Receptor, Serotonin, 5-HT2B / Q000378:metabolism; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*; D058826:Serotonin 5-HT2 Receptor Agonists; D012702:Serotonin Antagonists / Q000494:pharmacology / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D044403:Receptor, Serotonin, 5-HT2B; D058826:Serotonin 5-HT2 Receptor Agonists; D012702:Serotonin Antagonists; D010479:Pergolide; D000077465:Cabergoline; D008784:Methysergide